Monday, January 13, 2020 8:08:19 AM
“We are pleased by the rapid enrollment and dosing of the first patient in the Phase 3 pivotal study of our lead lysin candidate, exebacase, which we believe has the potential to improve clinical outcomes for patients suffering and dying from Staph aureus bacteremia, particularly those infected with difficult to treat methicillin-resistant Staph aureus (MRSA). We are confident in the protocol for the Phase 3 study which aims to be the first pivotal study to demonstrate superiority over standard of care antibiotics alone for the treatment of MRSA bacteremia,” said Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research and Development of ContraFect. “We believe exebacase and our pipeline of DLA candidates have the potential to be game changers in the fight against drug-resistant pathogens.”
The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the efficacy and safety of exebacase in approximately 350 patients with complicated Staph aureus bacteremia, including right-sided endocarditis. Patients entering the Phase 3 study will be randomized 2:1 to either exebacase or placebo, with all patients receiving standard-of-care antibiotics. The primary efficacy endpoint will be clinical response at Day 14 in patients with MRSA bacteremia, including right-sided endocarditis. Secondary endpoints will include clinical response at Day 14 in the All Staph aureus patients (MRSA and methicillin-sensitive Staph aureus (MSSA)), 30-day all-cause mortality in MRSA patients, and clinical response at later timepoints. The company plans to conduct an interim futility analysis following the enrollment of approximately 60% of the study population.
Recent CFRX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:24:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:30:55 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/03/2023 09:08:09 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/03/2023 04:16:01 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/30/2023 09:24:34 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/24/2023 08:06:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/23/2023 08:05:56 PM
- ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study • GlobeNewswire Inc. • 10/16/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 03:15:52 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/25/2023 12:00:18 PM
- ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development • GlobeNewswire Inc. • 09/19/2023 12:30:00 PM
- ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/14/2023 08:05:49 PM
- ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 • GlobeNewswire Inc. • 08/28/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2023 09:10:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:18:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:10:59 PM
- ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2023 08:33:29 PM
- ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million • GlobeNewswire Inc. • 06/27/2023 12:30:00 PM
- ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens • GlobeNewswire Inc. • 06/20/2023 12:59:00 PM
- ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023 • GlobeNewswire Inc. • 06/08/2023 08:01:00 PM
- ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2023 12:00:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM